Drug intelligence / Profile preview

TLC599

Development stage: Phase 3
Lead developer: Taiwan Liposome Company
Modality: Small Molecules
Administration: Intraarticular

Overview

TLC599 is a proprietary BioSeizer® formulation of dexamethasone sodium phosphate (DSP) designed for intra-articular injection in the treatment of osteoarthritis of the knee. It utilizes a multi-lamellar liposomal formulation to encapsulate DSP, enabling sustained release inside the joint while also containing free DSP for rapid onset of action. Clinical studies have shown that TLC599 can provide pain relief and functional improvement for up to 24 weeks after a single injection, with additional benefits when a second injection is administered at week 24, extending relief to 52 weeks.

Other names: Liposomal dexamethasone sodium phosphateBioSeizer dexamethasone sodium phosphate

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on TLC599.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLC599.

Explore the full profile